Lilia Fernández Selected Research

D 002

1/2017	Comparison of the efficacy and tolerability of chondroitin plus glucosamine and D-002 (beeswax alcohols) in subjects with osteoarthritis symptoms.
7/2013	Effects of D-002, a mixture of high molecular weight beeswax alcohols, on patients with nonalcoholic fatty liver disease.
4/2011	Evaluation of anti-inflammatory and antinociceptive effects of D-002 (beeswax alcohols).
1/2005	Effects of D-002, a product isolated from beeswax, on gastric symptoms of patients with osteoarthritis treated with piroxicam: a pilot study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lilia Fernández Research Topics

Disease

3	Intermittent Claudication 06/2008 - 01/2003
3	Headache (Headaches) 01/2005 - 09/2003
3	Hypertension (High Blood Pressure) 01/2005 - 01/2002
2	Osteoarthritis 01/2017 - 01/2005
2	Pain (Aches) 01/2017 - 01/2005
2	Myalgia 01/2003 - 01/2003
2	Myocardial Infarction 01/2003 - 01/2002
1	Prostatic Hyperplasia (Benign Prostatic Hyperplasia) 01/2019
1	Arthralgia (Joint Pain) 01/2017
1	Non-alcoholic Fatty Liver Disease 07/2013
1	Insulin Resistance 07/2013
1	Weight Loss (Weight Reduction) 07/2013
1	Pleurisy (Pleuritis) 04/2011
1	Granuloma 04/2011
1	Hypercholesterolemia 05/2006
1	Ulcer 01/2005
1	Rheumatoid Arthritis 01/2005
1	Stomach Ulcer (Gastric Ulcer) 01/2005
1	Duodenal Ulcer (Curling's Ulcer) 01/2005
1	Diarrhea 07/2004
1	Unstable Angina 07/2004
1	Heartburn (Pyrosis) 09/2003
1	Pruritus (Itching) 01/2003
1	Sleep Initiation and Maintenance Disorders (Insomnia) 01/2003
1	Type 2 Diabetes Mellitus (MODY) 01/2003
1	Gastritis 01/2003
1	Muscle Cramp (Cramp) 01/2003
1	Abdominal Pain (Pain, Abdominal) 01/2003
1	Coronary Disease (Coronary Heart Disease) 01/2002
1	Cerebrovascular Disorders (Cerebrovascular Occlusion) 01/2002
1	Cardiac Sudden Death (Sudden Cardiac Arrest) 01/2002

Drug/Important Bio-Agent (IBA)

8	policosanolIBA 06/2008 - 01/2002
4	beeswaxIBA 01/2017 - 01/2005
4	D 002IBA 01/2017 - 01/2005
3	LipidsIBA 01/2019 - 01/2002
3	AlcoholsIBA 01/2017 - 04/2011
2	Atorvastatin (Lipitor)FDA Link 01/2003 - 01/2003
2	oxidized low density lipoproteinIBA 01/2003 - 01/2002
1	Terazosin (Hytrin)FDA LinkGeneric 01/2019
1	ChondroitinIBA 01/2017
1	Glucosamine (Dona)IBA 01/2017
1	CarrageenanIBA 04/2011
1	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 06/2008
1	Analgesics (Analgesic Drugs)IBA 01/2005
1	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 01/2005
1	Proton Pumps (Proton Pump)IBA 01/2005
1	Piroxicam (Feldene)FDA LinkGeneric 01/2005
1	Ethanol (Ethyl Alcohol)IBA 01/2005
1	Ticlopidine (Ticlid)FDA LinkGeneric 07/2004
1	CholesterolIBA 01/2003
1	Glucose (Dextrose)FDA LinkGeneric 01/2003
1	Lovastatin (Mevacor)FDA LinkGeneric 01/2003

Therapy/Procedure

1	Complementary Therapies (Alternative Medicine) 07/2013
1	Diet Therapy (Therapy, Diet) 07/2013
1	Therapeutics 06/2008